Skip to content

Author

Sarah I. Othman

We have 4 of 32 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Breaking the Myb–KIX Alliance: Structure‐Guided Discovery of Biaryl Hydroxy‐Naphthamides as Disruptors of the c‐Myb–CBP/p300 KIX Protein–Protein Interaction

3‐hydroxy‐2‐naphthamides are established as promising scaffolds for targeting the c‐Myb–CBP/p300 KIX interface and are supported as the most conformationally stable interfacial binders.

H. Alfassam, Emadeldin M. Kamel, Sarah I. Othman et al. · 0 citations
Jul 2026

Structure-Guided Identification of 2-Arylbenzothiazole as disruptors for the Oncogenic MTDH-SND1 Protein-Protein Interaction.

2-arylbenzothiazoles are established as a promising chemotype for MTDH-SND1 PPI inhibition and provide a validated computational-to-experimental framework for discovering and optimizing MTDH-directed therapeutics.

Emadeldin M. Kamel, S. Khadrawy, A. A. Allam et al. · 0 citations
Open access Aug 2026

Structure‐Based Discovery of Fumiquinazolines as Skp2–Cks1 Protein–Protein Interaction Disruptors: Mechanistic Computational Insights and Experimental Validation

Findings identify Fumiquinazoline D as an early‐stage biochemical hit for disruption of the Skp2–Cks1 interaction and as a potential scaffold for further mechanistic validation and medicinal‐chemistry investigation.

Emadeldin M. Kamel, A. A. Allam, H. Rudayni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.